Clinical trial / 2014
Effects of selenium and vitamin E supplementation on prostate cancer risk varied by baseline selenium status.
In a case-cohort analysis of the SELECT trial, researchers evaluated whether baseline toenail selenium modified the effects of selenium and vitamin E on prostate cancer (PCa) risk. Selenium supplementation did not affect risk in men with low baseline selenium (<60th percentile) but increased high-grade PCa risk by 91% (P = .007) in men with higher baseline selenium. Vitamin E alone had no effect in men with high baseline selenium (≥40th percentile) but increased risks of total (63%, P = .02) and high-grade PCa (111%, P = .008) among men with lower baseline selenium status.
- Study type
- Case-cohort study within a randomized trial
- Who was studied
- 1739 total and 489 high-grade prostate cancer cases and 3117 men in a randomly selected subcohort from SELECT
- What was measured
- Total, low-grade, and high-grade (Gleason 7-10) prostate cancer risk
THE PAPER
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.
Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA. J Natl Cancer Inst, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.